Peptide stack
Tesamorelin + Ipamorelin
Same idea as CJC-1295 + ipamorelin, but with an FDA-approved GHRH backbone.
Components studied separately, not the combination
COMPONENTS in this stack
-
Tesamorelin
FDA-approved GHRH analog specifically approved for reducing visceral fat in HIV-associated lipodystrophy, used off-label more broadly for visceral fat reduction and as a growth-hormone secretagogue.
FDA-approved -
Ipamorelin
One of the most selective growth hormone secretagogues available. It stimulates GH release without the cortisol, prolactin or appetite spikes of older GHRPs, and is almost always paired with a GHRH analog like CJC-1295/Mod-GRF.
Research chemical
Why these are combined
Tesamorelin (Egrifta) has the best clinical trial record of any GHRH analog, shown to cut visceral fat and improve body composition in HIV-associated lipodystrophy. Ipamorelin adds ghrelin-receptor GH stimulation on top. No trial has tested this specific pairing outside that patient population.
Mechanism & pharmacokinetics
Same GHRH-receptor-plus-ghrelin-receptor logic as CJC-1295/ipamorelin, but with a clinically-trialed GHRH analog instead of a research one. Tesamorelin has a short half-life (roughly 26 to 38 minutes), so it's dosed daily to sustain GHRH-receptor stimulation; ipamorelin's ~2-hour half-life layers a sharper GH pulse on top through the separate ghrelin receptor. Because tesamorelin has real trial data behind it (unlike CJC-1295), this pairing has a firmer PK foundation for its individual components, even though the combination itself has never been studied directly.
Citations
Typical community protocol
Tesamorelin commonly 1-2 mg daily (approved dosing is 2 mg/day); ipamorelin 200-300 mcg daily. Often cycled 12-16 weeks, subcutaneous injection.
Safety notes
Community notes (anecdotal — not clinical evidence)
Popular because tesamorelin is an actual approved drug with real safety data, which gives the whole stack more credibility than most research-chemical combos.